FULCRUM THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
FULCRUM THERAPEUTICS, INC. (FULC) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $308.00K.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$908.00K, a 249.83% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2021 was $606.00K.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2020 was -$531.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $0.00 S-4 · filed 2026-09-02 | $0.00 derived: sum of 3 quarters · filed 2026-09-02 | $0.00 derived: sum of 4 quarters · filed 2026-09-02 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-04-27 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | $0.00 derived: sum of 3 quarters · filed 2026-09-02 | -$979.00K derived: sum of 4 quarters · filed 2026-09-02 | ||||
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | -$979.00K derived: sum of 3 quarters · filed 2026-09-02 | -$2.10M S-4 · filed 2026-09-02 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4 6 month · filed 2025-10-29 | -$979.00K derived: sum of 2 quarters · filed 2026-09-02 | -$2.10M 10-Q · filed 2025-10-29 | -$3.66M derived: sum of 4 quarters · filed 2026-09-02 | ||||
| 2025-06-30 | -$979.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | -$2.10M S-4 · filed 2026-09-02 | -$3.66M derived: sum of 3 quarters · filed 2026-09-02 | -$2.33M derived: sum of 4 quarters · filed 2026-09-02 | ||||
| 2025-03-31 | -$1.12M 10-Q · filed 2026-04-27 | -$2.68M derived: sum of 2 quarters · filed 2026-09-02 | -$1.35M derived: sum of 3 quarters · filed 2026-09-02 | $979.00K derived: sum of 4 quarters · filed 2026-09-02 | ||||
| 2024-12-31 | -$1.56M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | -$237.00K derived: sum of 2 quarters · filed 2026-09-02 | $2.10M derived: sum of 3 quarters · filed 2026-09-02 | $1.56M S-4 · filed 2026-09-02 | ||||
| 2024-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $3.66M derived: sum of 2 quarters · filed 2025-10-29 | $3.12M 10-Q · filed 2025-10-29 | $3.08M derived: sum of 4 quarters · filed 2025-10-29 | ||||
| 2024-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $1.80M 10-Q · filed 2025-07-29 | $1.75M derived: sum of 3 quarters · filed 2025-07-29 | $1.68M derived: sum of 4 quarters · filed 2025-07-29 | ||||
| 2024-03-31 | -$537.00K 10-Q · filed 2025-05-01 | -$580.00K derived: sum of 2 quarters · filed 2025-05-01 | -$656.00K derived: sum of 3 quarters · filed 2025-05-01 | -$99.00K derived: sum of 4 quarters · filed 2025-05-01 | ||||
| 2023-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$119.00K derived: sum of 2 quarters · filed 2025-02-25 | $438.00K derived: sum of 3 quarters · filed 2025-02-25 | $308.00K 10-K · filed 2025-02-25 | ||||
| 2023-09-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $481.00K derived: sum of 2 quarters · filed 2024-11-13 | $351.00K 10-Q · filed 2024-11-13 | -$904.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $557.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $427.00K 10-Q · filed 2024-07-31 | -$828.00K derived: sum of 3 quarters · filed 2024-07-31 | -$875.00K derived: sum of 4 quarters · filed 2024-07-31 | ||||
| 2023-03-31 | -$130.00K 10-Q · filed 2024-05-13 | $130.00K 10-Q · filed 2023-05-15 | -$1.39M derived: sum of 2 quarters · filed 2024-05-13 | -$1.43M derived: sum of 3 quarters · filed 2024-05-13 | -$1.37M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.30M derived: sum of 2 quarters · filed 2024-02-27 | -$1.24M derived: sum of 3 quarters · filed 2024-02-27 | -$908.00K 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $12.00K derived: sum of 2 quarters · filed 2023-11-07 | $347.00K 10-Q · filed 2023-11-07 | -$347.00K 10-Q · filed 2022-11-08 | $316.00K derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $394.00K 10-Q · filed 2023-08-03 | -$394.00K 10-Q · filed 2022-08-11 | $363.00K derived: sum of 3 quarters · filed 2023-08-03 | $874.00K derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $335.00K 10-Q · filed 2023-05-15 | -$335.00K 10-Q · filed 2022-05-09 | $304.00K derived: sum of 2 quarters · filed 2023-06-26 | $815.00K derived: sum of 3 quarters · filed 2023-06-26 | $940.00K derived: sum of 4 quarters · filed 2023-06-26 | |||
| 2021-12-31 | -$31.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $480.00K derived: sum of 2 quarters · filed 2023-06-26 | $605.00K derived: sum of 3 quarters · filed 2023-06-26 | $606.00K 10-K/A · filed 2023-06-26 | ||||
| 2021-09-30 | $511.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $636.00K derived: sum of 2 quarters · filed 2022-11-08 | $637.00K 10-Q · filed 2022-11-08 | -$486.00K derived: sum of 4 quarters · filed 2023-06-26 | ||||
| 2021-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $126.00K 10-Q · filed 2022-08-11 | -$997.00K derived: sum of 3 quarters · filed 2023-06-26 | -$1.16M derived: sum of 4 quarters · filed 2023-06-26 | ||||
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-09 | -$1.12M derived: sum of 2 quarters · filed 2023-06-26 | -$1.28M derived: sum of 3 quarters · filed 2023-06-26 | -$855.00K derived: sum of 4 quarters · filed 2023-06-26 | ||||
| 2020-12-31 | -$1.12M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$1.29M derived: sum of 2 quarters · filed 2023-06-26 | -$856.00K derived: sum of 3 quarters · filed 2023-06-26 | -$531.00K 10-K/A · filed 2023-06-26 | $531.00K 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $267.00K derived: sum of 2 quarters · filed 2021-11-04 | $592.00K 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $430.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $755.00K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $325.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |